NCT07286032

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.

Conditions

• Patients With Chemotherapy-Induced Thrombocytopenia

Interventions

Type	Name	Description
DRUG	Hetrombopag Olamine	For Part A, all participants would receive hetrombopag treatment.
DRUG	Hetrombopag Olamine ；Hetrombopag Olamine Placebo	For Part B，participants would be randomized to receive hetrombopag treatment or matching placebo, respectively。

Timeline

• Start date: 2026-02-01
• Primary completion: 2028-12-01
• Completion: 2029-06-01
• First posted: 2025-12-16
• Last updated: 2025-12-16

Regulatory

• FDA-regulated drug study